Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel
17 mars 2020 13h06 HE
|
Todos Medical Ltd.
3DMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial Nucleic Acid test performed on proprietary automated platform to increase throughput CE Mark and China FDA...
UPDATE: Todos Medical Enters Into Coronavirus Nucleic Acid Buccal Testing Kit Distribution Agreement With 3D BioMed
17 mars 2020 11h30 HE
|
Todos Medical Ltd.
3D BioMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial Nucleic Acid test performed on proprietary automated platform to increase throughput CE Mark and Chinese...
Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
06 févr. 2020 08h11 HE
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
Amarantus Releases Letter to Shareholders
04 févr. 2020 09h54 HE
|
Amarantus Bioscience Holdings, Inc.
New York, NY, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary...
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
30 janv. 2020 09h05 HE
|
Amarantus Bioscience Holdings, Inc.
Strong customer retention at both stores in Dallas, TX with growing online presence Focus on delivering wellness solutions by engaging customers to participate in clinical studies and provide...
Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
02 janv. 2020 08h14 HE
|
Amarantus Bioscience Holdings, Inc.
Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02,...
Todos To Present At Upcoming 12th Annual LD Micro Main Event
06 déc. 2019 07h29 HE
|
Todos Medical Ltd.
REHOVOT, Israel, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection...
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
04 déc. 2019 07h36 HE
|
Amarantus Bioscience Holdings, Inc.
· Patent extends patent coverage for eltoprazine to 2034 New York, NY, Dec. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS)...
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
21 nov. 2019 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC...
Amarantus Provides Recapitalization Update to Shareholders
18 nov. 2019 08h30 HE
|
Amarantus Bioscience Holdings, Inc.
Pending license with Emerald provides opportunity to realize therapeutic portfolio valueJV w/Todos announces full enrollment for LymPro Alzheimer’s blood test clinical trialAmarantus management...